Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68 | Zendy

Liang Sun | Zendy; Adam Meijer | Zendy; Matheus Froeyen | Zendy; Linlin Zhang | Zendy; Hendrik Jan Thibaut | Zendy; Jim Baggen | Zendy; Shyla George | Zendy; John Vernachio | Zendy; Frank J. M. van Kuppeveld | Zendy; Pieter Leyssen | Zendy; Rolf Hilgenfeld | Zendy; Johan Neyts | Zendy; Leen Delang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68

Author(s) -

Liang Sun,

Adam Meijer,

Matheus Froeyen,

Linlin Zhang,

Hendrik Jan Thibaut,

Jim Baggen,

Shyla George,

John Vernachio,

Frank J. M. van Kuppeveld,

Pieter Leyssen,

Rolf Hilgenfeld,

Johan Neyts,

Leen Delang

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01375-15

Subject(s) - favipiravir , virology , enterovirus , protease , virus , broad spectrum , enterovirus 71 , biology , drug resistance , microbiology and biotechnology , chemistry , enzyme , medicine , infectious disease (medical specialty) , covid-19 , disease , biochemistry , pathology , combinatorial chemistry

We investigated the susceptibility of 10 enterovirus D68 (EV-D68) isolates (belonging to clusters A, B, and C) to (entero)virus inhibitors with different mechanisms of action. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn were more effective than vapendavir and pirodavir. Favipiravir proved to be a weak inhibitor. Resistance to pleconaril maps to V69A in the VP1 protein, and resistance to rupintrivir maps to V104I in the 3C protease. A structural explanation of why both substitutions may cause resistance is provided.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research